

Table S1. Patient characteristics

Patient ID	Age (y)	Sex	Disease *	Cytogenetics	Blast score	ANC score	Hemoglobin score	Platelet score	Cytogenetic score	IPSS-R score	IPSS-R category	Treatment & Disease evolution	(%) HMGB **
0003	61	M	MDS-U	47,XY,+8[16]/46,XY[4]	3	0	0	1	2	6	High	Azacitidine. Progression to AML	37.8
0042	64	M	RAEB-2	Complex, greater than 3 abnormalities	3	0	1	1	4	9	Very high	No treatment	78.3
0059	62	F	MDS-U	Normal	0	0	1.5	0.5	1	3	Low	Azacitidine	55.4
0249	60	M	RAEB-1	Complex, greater than 3 abnormalities	3	0	0	1	4	8	Very high	No treatment	85.4
0252	71	M	RCMD	47,XY,+8[11]/46,XY[9]	1	0	1	0.5	2	4.5	Intermediate	No treatment	98.7
0405	87	M	RA	Normal	1	0	1	0	1	3	Low	No treatment	97
0427	70	M	MDS-U	Normal	3	0	1	0.5	1	5.5	High	Azacitidine & Decitabine. Progression to AML	99.5
0442	62	M	MDS-U	47,XY,+8[2]/46,XY,del(13)(q12q22)[2]/46,XY[16]	2	0	0	0	2	4	Intermediate	Azacitidine	99.2
0448	66	M	MDS-U	Normal	2	0	0	0	1	3	Low	No treatment	99.5
0449	66	M	MDS-U	Normal	2	0	0	0	0	2	Low	No treatment	99.5
0460	62	M	MDS-U	46,XY,del(7)(q11.2)[1]/46,XY[18]	3	0	1	0	2	6	High	No treatment	99.9
0461	38	F	MDS-U	Normal	1	0	1	0	0	2	Low	No treatment	99.2
0471	63	M	MDS-U	46,XY,del(7)(q22),del(20)(q11.2q13.1)[13]/46,XY[7]	1	0	0	0.5	3	4.5	Intermediate	No treatment	70.9

* MDS-U, myelodysplastic syndrome-unclassified; RAEB-2, Refractory anaemia with excess blasts-2; RAEB-1, Refractory anaemia with excess blasts-1; RA, Refractory anaemia; RCMD, Refractory cytopenia with multilineage dysplasia

** Percentage of HMGB1 from CD34+ cells by flow cytometric analysis